Distinct effects of CAR8–10 and PXR6,11 activation in the regulation of cholesterol homeostasis are challenging to discern, as simultaneous CAR activation and PXR antagonism may exhibit additive effects in the treatment of pathological hypercholesterolemia or other metabolic diseases. Here, NR1I3 is linked to metabolic disease.